Iron Deficiency Plays Essential Roles in the Trigger, Treatment, and Prognosis of Autosomal Dominant Hypophosphatemic Rickets

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2020 Sep 30

PMID 32995940

Citations 4

Authors

C Liu

X Li

Z Zhao

Y Chi

L Cui

Q Zhang

F Ping

X Chai

Y Jiang

O Wang

M Li

X Xing

W Xia

Affiliations

Soon will be listed here.

Abstract

Introduction: Autosomal dominant hypophosphatemic rickets (ADHR) is unique for its incomplete penetrance, variety of disease onsets, and waxing and waning phenotypes. Iron deficiency is a trigger of ADHR. This study aimed to clarify the role of iron deficiency in ADHR.

Methods: Data of clinical manifestations and laboratory examinations were collected from patients among eight kindreds with ADHR. Multiple regression and Pearson's correlation tests were performed to test the relationships of serum phosphate levels and other laboratory variables during the patients' follow-ups.

Results: Among 23 ADHR patients with fibroblast growth factor 23 (FGF23) mutations, 14 patients presented with obvious symptoms. Ten patients had iron deficiency at the onset of ADHR, coinciding with menarche, menorrhagia, pregnancy, and chronic gastrointestinal bleeding. Two patients who did not have their iron status tested presented with symptoms after abortion and pregnancy in one patient each, which suggested that they also had iron deficiency at onset. Patients were treated with ferrous succinate tablets, vitamin C, and neutral phosphate and calcitriol. With correction of the iron status, the patients' symptoms showed notable improvement, with increased serum phosphate levels. Two patients' FGF23 levels also declined to the normal range. There were strong correlations between serum phosphate and serum iron levels (r = 0.7689, p < 0.0001), serum ferritin levels (r = 0.5312, p = 0.002), iron saturation (r = 0.7907, p < 0.0001), and transferrin saturation (r = 0.7875, p < 0.001). We also examined the relationships between serum phosphate levels and hemoglobin-related indices, which were significant (hemoglobin: r = 0.71, p < 0.0001; MCV: r = 0.7589, p < 0.0001; MCH: r = 0.8218, p < 0.0001; and MCHC: r = 0.7751, p < 0.0001). Longitudinal data of six patients' follow-up also showed synchronous changes in serum phosphate with serum iron levels.

Conclusions: Iron deficiency plays an important role in triggering ADHR. Monitoring and correcting the iron status are helpful for diagnosing and treating ADHR. Iron metabolism parameters and hemoglobin-related parameters are positively correlated with serum phosphate levels in patients with ADHR and iron deficiency, and these might serve as good indicators of prognosis of ADHR.

Citing Articles

Recent advances in the application of ionomics in metabolic diseases.

Zhang Y, Huang B, Jin J, Xiao Y, Ying H Front Nutr. 2023; 9:1111933.

PMID: 36726817 PMC: 9884710. DOI: 10.3389/fnut.2022.1111933.

Phosphate Homeostasis and Disorders of Phosphate Metabolism.

Perumal N, Padidela R Curr Pediatr Rev. 2022; 20(4):412-425.

PMID: 36545737 DOI: 10.2174/1573396319666221221121350.

Hereditary Rickets: A Quick Guide for the Pediatrician.

Alsubaihin A, Harrington J Curr Pediatr Rev. 2022; 20(4):380-394.

PMID: 36475338 DOI: 10.2174/1573396319666221205123402.

Rickets guidance: part I-diagnostic workup.

Haffner D, Leifheit-Nestler M, Grund A, Schnabel D Pediatr Nephrol. 2021; 37(9):2013-2036.

PMID: 34910242 PMC: 9307538. DOI: 10.1007/s00467-021-05328-w.

References

Econs M, McEnery P . Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab. 1997; 82(2):674-81. DOI: 10.1210/jcem.82.2.3765. View

Imel E, Hui S, Econs M . FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res. 2007; 22(4):520-6. DOI: 10.1359/jbmr.070107. View

Gribaa M, Younes M, Bouyacoub Y, Korbaa W, Ben Charfeddine I, Touzi M . An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation. J Bone Miner Metab. 2009; 28(1):111-5. DOI: 10.1007/s00774-009-0111-5. View

Bai X, Miao D, Goltzman D, Karaplis A . The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem. 2003; 278(11):9843-9. DOI: 10.1074/jbc.M210490200. View

White K, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom T, Econs M . Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001; 60(6):2079-86. DOI: 10.1046/j.1523-1755.2001.00064.x. View

Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y . FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19(3):429-35. DOI: 10.1359/JBMR.0301264. View

Kato K, Jeanneau C, Tarp M, Benet-Pages A, Lorenz-Depiereux B, Bennett E . Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem. 2006; 281(27):18370-7. DOI: 10.1074/jbc.M602469200. View

Tagliabracci V, Engel J, Wiley S, Xiao J, Gonzalez D, Appaiah H . Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci U S A. 2014; 111(15):5520-5. PMC: 3992636. DOI: 10.1073/pnas.1402218111. View

Clinkenbeard E, Farrow E, Summers L, Cass T, Roberts J, Bayt C . Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J Bone Miner Res. 2013; 29(2):361-9. PMC: 5240191. DOI: 10.1002/jbmr.2049. View

10.

Farrow E, Yu X, Summers L, Davis S, Fleet J, Allen M . Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011; 108(46):E1146-55. PMC: 3219119. DOI: 10.1073/pnas.1110905108. View

11.

Imel E, Peacock M, Gray A, Padgett L, Hui S, Econs M . Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab. 2011; 96(11):3541-9. PMC: 3205884. DOI: 10.1210/jc.2011-1239. View

12.

Liu C, Zhao Z, Wang O, Li M, Xing X, Hsieh E . Earlier Onset in Autosomal Dominant Hypophosphatemic Rickets of R179 than R176 Mutations in Fibroblast Growth Factor 23: Report of 20 Chinese Cases and Review of the Literature. Calcif Tissue Int. 2019; 105(5):476-486. DOI: 10.1007/s00223-019-00597-y. View

13.

Furuyama K, Kaneko K, Vargas P . Heme as a magnificent molecule with multiple missions: heme determines its own fate and governs cellular homeostasis. Tohoku J Exp Med. 2007; 213(1):1-16. DOI: 10.1620/tjem.213.1. View

14.

Gkouvatsos K, Papanikolaou G, Pantopoulos K . Regulation of iron transport and the role of transferrin. Biochim Biophys Acta. 2011; 1820(3):188-202. DOI: 10.1016/j.bbagen.2011.10.013. View

15.

Kassebaum N, Jasrasaria R, Naghavi M, Wulf S, Johns N, Lozano R . A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2013; 123(5):615-24. PMC: 3907750. DOI: 10.1182/blood-2013-06-508325. View

16.

Hanudel M, Chua K, Rappaport M, Gabayan V, Valore E, Goltzman D . Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. Am J Physiol Renal Physiol. 2016; 311(6):F1369-F1377. PMC: 5210202. DOI: 10.1152/ajprenal.00281.2016. View

17.

Koury M, Haase V . Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol. 2015; 11(7):394-410. PMC: 4497972. DOI: 10.1038/nrneph.2015.82. View

18.

Hanudel M, Eisenga M, Rappaport M, Chua K, Qiao B, Jung G . Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrol Dial Transplant. 2018; 34(12):2057-2065. PMC: 6888066. DOI: 10.1093/ndt/gfy189. View

19.

Toro L, Barrientos V, Leon P, Rojas M, Gonzalez M, Gonzalez-Ibanez A . Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury. Kidney Int. 2018; 93(5):1131-1141. DOI: 10.1016/j.kint.2017.11.018. View

20.

Coe L, Madathil S, Casu C, Lanske B, Rivella S, Sitara D . FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem. 2014; 289(14):9795-810. PMC: 3975025. DOI: 10.1074/jbc.M113.527150. View